65,437 trials
Hypertension
Primary: Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg Plus ISMN 60 mg Versus Single Dose of Losartan 100 mg — -24.9; -1.8 Percent…
Pain, Postoperative · Hernia, Inguinal
Primary: Modified Brief Pain Inventory-Short Form (mBPI-sf): Worst Pain 24 Hours Post Surgery — 5.2; 5.4; 4.7; 5.4 scores on scale — p=0.0668
Schizophrenia
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 177; 32 Participants
Cutaneous Leishmaniasis
Primary: Complete Clinical Response — 85; 103; 86 participants
Stable Angina
Primary: C-reactive Protein — -16; -11 Percentage — p=0.3
Lymphoma, Non-Hodgkin · Multiple Myeloma
Primary: Overall Participant Counts of Adverse Events (AEs) Up to Twelve Months Post Transplant — 7; 6; 1; 12 participants
Vaccines, Pneumococcal
Primary: Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Infant Series — 1.33…
Pneumonia · Malaria
Primary: Number of Children Who Received Early and Appropriate Treatment for Pneumonia. — 247; 27 partcipants
Type 2 Diabetes Mellitus · Hypercholesterolemia · Pre-diabetes
Primary: Percent Change of Hemoglobin A1C (HbA1C) From Baseline to 16 Weeks When Given as Initial Therapy to Drug-naïve, Diabetic Subjects. — -0.83; -1.09 Percentage of change of…
Actinic Keratoses
Primary: Number of Participants With Recurrence of AK Lesions — 52; 41 participants
Rheumatoid Arthritis
Primary: Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12 — 106; 59 participants — p=<0.001
Perennial Allergic Rhinitis
Primary: Change in 4 Nasal Symptom Score (Sneezing Attack, Rhinorrhea, Nasal Congestion, and Nasal Itching) After 2 Weeks — 7.84; 8.41; 8.27; 8.29 Units on a scale — p=0.0001
Osteoporosis, Postmenopausal · Back Pain · Spinal Fracture
Primary: Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 6-Month Endpoint — 206; 193; 142; 143 participants — p=0.642
Myopia · Hyperopia
Primary: Corneal Sensitivity — 26.9; 25.5 percent CO2
Elderly · Epilepsy · Seizures
Primary: Effectiveness of Medication as Measured by Participation Through the End of the Trial. — 14 participants